
The FDA has identified compliance issues at Novo Nordisk's manufacturing facility in Indiana, which is crucial for producing drugs for various biotech companies. This non-compliance status may cause delays in the approval process for medications manufactured at the site.

The Trump administration has been reducing scientific expertise and patient perspectives within federal health agencies as part of efforts to streamline the government. This has led to the removal of experts who provided ethical guidance and evaluated the impact of scientific research.